Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chiglitazar Added to Insulin Glargine in Type 2 Diabetes
NCT06007014Not yet recruiting
- Start
- Oct 2023
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of chiglitazar in type 2 diabetes mellitus (T2DM) (2 arms). Primary endpoint: Glycosylated hemoglobin at 18 weeks. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
chiglitazar
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06007014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06007014.